A Phase 2 Trial of 4 Weeks of ACH-126,443 in Comparison With Continued Lamivudine in Stable Triple Antiretroviral Combination Therapy in HIV-Infected Subjects With Modestly Detectable Viral Load

Trial Profile

A Phase 2 Trial of 4 Weeks of ACH-126,443 in Comparison With Continued Lamivudine in Stable Triple Antiretroviral Combination Therapy in HIV-Infected Subjects With Modestly Detectable Viral Load

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2009

At a glance

  • Drugs Antiretrovirals; Elvucitabine; Lamivudine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Aug 2009 Planned number of patients (60) added as reported by ClinicalTrials.gov.
    • 25 Aug 2009 Planned end date (May 2003) added as reported by ClinicalTrials.gov.
    • 25 Aug 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top